GO:0000338 protein deneddylation: Mechanism and Genes

Protein deneddylation (GO:0000338) is the enzymatic removal of the ubiquitin-like modifier NEDD8 from a substrate protein. The most extensively characterized substrates are the cullin scaffold proteins of Cullin-RING ubiquitin ligases (CRLs), which require neddylation for full ligase activity; deneddylation therefore acts as a dynamic switch that controls CRL-dependent protein turnover. Because CRLs regulate the stability of many short-lived regulators, the balance between neddylation and deneddylation has broad consequences for cell cycle progression, signal transduction and stress responses. The process is conserved and has been studied in organisms ranging from yeast to mammals, with cullin deneddylation being the canonical synonym for GO:0000338. Beyond cullins, deneddylation targets include ribosomal proteins, where removal of NEDD8 promotes synergy between the NEDD8-activating enzyme inhibitor MLN4924 and chemotherapy to elicit complete therapeutic responses in preclinical models. In the heart, cullin deneddylation suppresses the necroptotic pathway in cardiomyocytes, linking the NEDD8 cycle to cell-death decisions and cardiac homeostasis. In hepatocellular carcinoma, SDHA/B reduction facilitates deNEDDylation of cullin1 and stabilizes YAP/TAZ, promoting tumor growth. These examples show that GO:0000338 is not a housekeeping side reaction but a regulatory node with direct disease relevance. For researchers, protein deneddylation matters because it determines the abundance and activity of CRL substrate receptors, influences cullin protein accumulation, and can be targeted pharmacologically. Inhibition of deneddylation, for example by blocking the NEDD8 pathway, triggers autoubiquitination of DDB1 within CRL4 complexes, revealing feedback between deneddylation and CRL4 integrity. Deneddylation also intersects with autophagy and ferroptosis, as shown for aloin, which suppresses cancer cell growth via autophagy-promoted NEDD8 de-NEDDylation targeting GPX4. Understanding GO:0000338 therefore requires both mechanistic biochemistry and disease-relevant cell models.

In our own words, protein deneddylation (GO:0000338) is the biochemical process that cleaves the covalent attachment between a target protein and the ubiquitin-like protein NEDD8, thereby reversing neddylation. The QuickGO definition states that it is the removal of a ubiquitin-like protein of the NEDD8 type from a protein, and the synonym cullin deneddylation reflects the fact that cullins are the best-studied substrates. This process is distinct from deubiquitination because it acts on NEDD8 rather than ubiquitin, although some enzymes may act on both modifiers. Deneddylation can be constitutive or regulated, and it controls the lifetime and activity of neddylated proteins, especially CRL components.

Protein deneddylation is important because it sets the steady-state level of neddylated cullins and thereby tunes the activity of Cullin-RING ligases, which control the degradation of many regulatory proteins. Perturbing this process changes cullin accumulation and CRL substrate receptor function, with consequences for cell proliferation, death and stress responses. In disease contexts, deneddylation has been linked to hepatocellular carcinoma progression through cullin1 deNEDDylation and YAP/TAZ stabilization, to suppression of necroptosis in cardiomyocytes, and to ferroptosis induction in cancer cells. The NEDD8 cycle is also a therapeutic target: MLN4924 and related strategies exploit deneddylation-dependent vulnerabilities, including synergy with chemotherapy via ribosomal protein deneddylation. Consequently, GO:0000338 is a central process for understanding both basic CRL biology and translational opportunities in oncology and cardiovascular disease.

The following genes and proteins are central to protein deneddylation (GO:0000338) and its regulation, based on the cited literature.

Protein deneddylation is regulated at multiple levels. The cycle is inherently dynamic, with neddylation and deneddylation acting in opposition to control cullin modification status. Inhibition of deneddylation, for example by perturbing the NEDD8 pathway, causes accumulation of neddylated cullins and can trigger feedback such as DDB1 autoubiquitination within CRL4. Metabolic signals also impinge on the process: reduction of SDHA/B promotes deNEDDylation of cullin1, linking mitochondrial function to deneddylation and YAP/TAZ stabilization. In cardiomyocytes, cullin deneddylation suppresses necroptotic signaling, indicating that cell-stress pathways can modulate the process. Autophagy has been reported to promote NEDD8 de-NEDDylation targeting GPX4, adding another layer of regulation. Finally, ribosomal protein deneddylation can be influenced by pharmacological inhibition of NEDD8 activation, which sensitizes cells to chemotherapy.

Deneddylation is directly implicated in cancer biology. In hepatocellular carcinoma, SDHA/B reduction promotes deNEDDylation of cullin1 and stabilizes YAP/TAZ, thereby promoting tumor growth. Aloin suppresses cancer cell growth via autophagy-promoted NEDD8 de-NEDDylation that targets GPX4 for ferroptosis induction, showing that manipulating deneddylation can be therapeutically beneficial. Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses, highlighting the translational potential of targeting this process. Inhibition of deneddylation also affects CRL4 integrity through DDB1 autoubiquitination, which may influence drug sensitivity.

In cardiac biology, neddylation and deneddylation are recognized as important regulatory processes. Cullin deneddylation suppresses the necroptotic pathway in cardiomyocytes, suggesting that enhancing deneddylation could protect against necroptosis-associated cardiac injury. Because necroptosis contributes to ischemia-reperfusion damage and heart failure, the NEDD8 cycle represents a potential therapeutic node in cardiovascular disease.

Adenosine and gastrointestinal inflammation have been studied in the context of NEDD8-related pathways, linking deneddylation biology to inflammatory signaling. Although the precise mechanisms remain to be fully defined, the connection suggests that deneddylation may modulate immune and inflammatory responses in the gut. This is consistent with the broader role of CRL-dependent protein turnover in inflammation.

Deneddylation can influence ferroptosis through GPX4 targeting, as shown for aloin-induced autophagy-promoted NEDD8 de-NEDDylation. Because ferroptosis is an iron-dependent form of cell death driven by lipid peroxidation, this link places GO:0000338 in the oxidative-stress response network. Targeting deneddylation may therefore be a strategy to sensitize cancer cells to ferroptosis-inducing therapies.

Western blotting with anti-NEDD8 or anti-cullin antibodies is a standard method to monitor deneddylation, because neddylated cullins migrate at a higher apparent molecular weight than unmodified cullins. This approach can detect accumulation of neddylated CUL1 and CUL3 upon deneddylation inhibition and is often used together with CRL activity assays. In CRL4 studies, DDB1 autoubiquitination can be monitored as a downstream readout of deneddylation inhibition.

Mass spectrometry-based proteomics can identify NEDD8-modified proteins and quantify changes in their modification state upon deneddylation perturbation. This is particularly useful for discovering non-cullin substrates such as ribosomal proteins and for linking deneddylation to specific cellular pathways. Proteomic profiling can also reveal downstream effects on YAP/TAZ or GPX4 stability in disease models.

Because deneddylation influences cancer cell growth and ferroptosis, viability assays, colony formation and lipid peroxidation measurements are commonly used to test the functional consequences of manipulating the process. Synergy between MLN4924 and chemotherapy can be assessed using combination index analysis in cancer cell lines. Necroptosis in cardiomyocytes can be measured using viability and phospho-MLKL readouts.

CRISPR knockout and knock-in screens can identify genes that modify deneddylation sensitivity, including cullin components, deneddylases and downstream effectors. Such screens are valuable for mapping the genetic network around GO:0000338 and for discovering combination targets with NEDD8-pathway inhibitors. Functional validation typically involves focused KO or point-mutation models.

Researchers studying protein deneddylation-related genes often need to determine whether a candidate gene is causally involved in the process or is merely correlated with changes in neddylation status. This requires precise genetic models that can knock out, mutate, tag or overexpress the gene of interest in relevant cell types. EDITGENE provides end-to-end CRISPR services to build such models and to support functional validation of deneddylation biology.

Protein deneddylation (GO:0000338) is a conserved regulatory process that removes NEDD8 from cullins and other substrates, thereby controlling CRL activity, protein stability and cell fate decisions. Its importance spans cancer, cardiac biology, ferroptosis and inflammation, with direct links to hepatocellular carcinoma, necroptosis suppression and chemotherapy synergy. As a result, deneddylation is both a fundamental research topic and a potential therapeutic target. Researchers can now dissect this process using CRISPR knockout, point-mutation, knock-in and overexpression models combined with proteomics and functional assays. EDITGENE supports these efforts with custom cell-model generation, library screening and bioinformatics services tailored to protein deneddylation research.